List of Excipients in Branded Drug BUPRENORPHINE TRANSDERMAL SYSTEM

« Back to Dashboard

Generic Drugs Containing BUPRENORPHINE TRANSDERMAL SYSTEM

Company	Ingredient	NDC	Excipient
Alvogen Inc	buprenorphine	47781-406	LEVULINIC ACID
Alvogen Inc	buprenorphine	47781-406	OLEYL OLEATE
Alvogen Inc	buprenorphine	47781-406	POVIDONE K90

What are the Most Frequently-Used Excipients in BUPRENORPHINE TRANSDERMAL SYSTEM?

# Of NDCs	Excipient
1	LEVULINIC ACID
1	OLEYL OLEATE
1	POVIDONE K90

Buprenorphine Transdermal System Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

Buprenorphine transdermal systems offer commercial opportunities in generic substitution, adhesive performance, skin tolerability, formulation lifecycle management, and contract manufacturing. The core formulation challenge is delivering a potent, low-dose opioid through skin at a controlled rate for seven days while maintaining adhesion and limiting irritation.

The reference product, Butrans, delivers buprenorphine at nominal rates of 5, 7.5, 10, 15, and 20 micrograms per hour. Its drug-in-adhesive system uses polyisobutylene, polybutene, povidone, oleic acid, and levulinic acid as inactive ingredients, with polyester backing and a removable release liner.[1] The principal formulation opportunity is not simply replacing an excipient. It is reproducing the reference product's flux, adhesion, residual drug content, crystallization profile, and seven-day wear performance.

What is the formulation architecture of a buprenorphine transdermal system?

The Butrans system is a multilayer drug-in-adhesive patch. Buprenorphine is incorporated into an adhesive matrix that contacts the skin directly. The patch generally contains:

Layer	Function	Commercial relevance
Backing layer	Protects the drug matrix from the environment	Controls moisture transmission, drug loss, and mechanical strength
Drug-in-adhesive matrix	Stores and releases buprenorphine	Determines drug loading, diffusion, adhesion, and skin flux
Release liner	Protects the adhesive before application	Affects drug transfer, liner removal, and manufacturing yield
Printed or external layer	Supports identification and handling	Requires ink compatibility and extractables control

The reference formulation uses a hydrophobic adhesive environment based on polyisobutylene and polybutene. Povidone contributes to drug dispersion and matrix properties. Oleic acid and levulinic acid act as permeation-enhancing components and influence buprenorphine partitioning into skin.[1]

The system is designed for continuous delivery over seven days. Patch area increases with nominal delivery rate, allowing commercial products to use a broadly similar matrix across multiple strengths.

Which excipients are used in buprenorphine transdermal systems?

The principal excipients disclosed in the U.S. Butrans labeling are:

Excipient	Likely formulation function	Key development risks
Polyisobutylene	Primary pressure-sensitive adhesive and matrix former	Cohesion, cold flow, residue, adhesive failure
Polybutene	Adhesive modifier and plasticizing component	Tack, viscosity, migration, aging
Povidone	Drug-dispersion aid and matrix modifier	Moisture sensitivity, molecular-weight effects, crystallization
Oleic acid	Skin permeation enhancer and plasticizing component	Irritation, oxidation, odor, flux variability
Levulinic acid	Permeation enhancer and chemical modifier	Skin tolerability, stability, pH-related behavior
Polyester backing	Mechanical and environmental barrier	Moisture transmission, flexibility, print compatibility
Release-liner materials	Protect the adhesive before use	Silicone transfer, peel force, drug adsorption

The exact grades, ratios, processing conditions, and residual solvent profile are critical. A generic product with the same named excipients can still fail comparative performance if adhesive rheology or enhancer distribution differs from the reference system.

How do excipients control buprenorphine skin permeation?

Buprenorphine has high potency, allowing transdermal delivery at low mass flux. The formulation must balance three variables:

1. Drug solubility in the adhesive matrix.
2. Partitioning from the matrix into stratum corneum.
3. Diffusion through the skin into systemic circulation.

Oleic acid is commonly used in transdermal systems because it can disrupt lipid organization in the stratum corneum. Levulinic acid may modify the local chemical environment and support permeation. These enhancers can increase delivery, but excessive enhancer concentration can produce erythema, edema, burning, or delayed skin recovery.

Povidone can help maintain a uniform drug phase. Its interaction with buprenorphine, acids, and the hydrophobic adhesive can affect crystallization. Visible crystals or drug-rich domains may cause declining flux, dose dumping risk, or batch-to-batch variability.

Polyisobutylene and polybutene determine the matrix's viscoelastic profile. A formulation with excessive tack may leave residue or deform during application. A matrix with insufficient tack may fail during bathing, exercise, or routine movement. The target is a balance between peel adhesion, shear resistance, cold flow, and clean removal.

What excipient strategy is most attractive for generic buprenorphine patches?

The strongest generic strategy is usually a reference-matched formulation with controlled excipient variation rather than a radically different platform.

Reference-matched adhesive matrix

A polyisobutylene-polybutene matrix offers the lowest technical risk because it aligns with the established product architecture. Development priorities include:

• Matching adhesive solids content.
• Controlling polymer molecular weight and viscosity.
• Reproducing enhancer-to-polymer ratios.
• Controlling buprenorphine particle size and solid-state form.
• Demonstrating uniform coating across all patch strengths.
• Matching seven-day adhesion and drug release.

Alternative acrylic or silicone systems

Acrylic and silicone adhesives may offer improved wear, lower residue, or better processing. They also create greater regulatory and bioequivalence risk. A platform change can alter:

• Buprenorphine thermodynamic activity.
• Skin permeation rate.
• Adhesive interactions with oleic or levulinic acid.
• Residual drug after seven days.
• Irritation and sensitization.
• In vitro release and permeation profiles.

An alternative adhesive may be commercially attractive if it solves a documented weakness of the reference product. It is less attractive when the only objective is a conventional ANDA because formulation differences increase the need for comparative performance evidence.

What formulation patents protect buprenorphine transdermal systems?

Patent protection for buprenorphine patches can cover the drug-in-adhesive composition, permeation-enhancer combinations, multilayer construction, dosage strengths, manufacturing processes, and methods of treating chronic pain. Patent analysis should distinguish:

• Composition-of-matter claims covering the adhesive matrix.
• Formulation claims covering polymer and enhancer combinations.
• Device claims covering patch layers and release liners.
• Manufacturing claims covering coating, drying, laminating, and die-cutting.
• Method-of-use claims covering opioid-naive patients, chronic pain, or dosing regimens.

The relevant U.S. regulatory record is the FDA Orange Book for listed patents and exclusivity, paired with USPTO patent records and Paragraph IV litigation data.[2][3] Patent expiration does not by itself establish commercial entry. A listed patent may be challenged, disclaimed, licensed, or subject to settlement restrictions.

For commercial diligence, the key question is whether a generic applicant can design around composition claims while retaining equivalent delivery performance. Adhesive and permeation-enhancer claims can create more meaningful formulation barriers than broad claims directed only to buprenorphine delivery.

When does buprenorphine transdermal exclusivity end?

Butrans received FDA approval in 2010 for the management of pain severe enough to require a continuous, around-the-clock opioid analgesic for an extended period.[1] The product's market protection has been shaped by regulatory exclusivity, listed patents, generic approvals, and Paragraph IV challenges.

FDA approval status and Orange Book listings should be evaluated separately:

Protection category	Relevance to buprenorphine transdermal products
New chemical entity exclusivity	Historical protection associated with the original buprenorphine transdermal approval
Listed patents	May delay ANDA approval or create litigation exposure
Pediatric exclusivity	Applies only if granted for qualifying studies
Orphan exclusivity	Generally not the principal protection for Butrans
Regulatory labeling	Controls whether a generic can use the same indication and instructions
Trade secrets	May protect coating, drying, mixing, and scale-up processes

The commercial window for generic competition depends on the earliest enforceable barrier, the outcome of Paragraph IV litigation, and any settlement terms. A company assessing entry should not rely on the branded product's original approval date alone.

What Paragraph IV challenges and litigation affect buprenorphine patches?

Paragraph IV applicants can challenge Orange Book patents by asserting invalidity, unenforceability, or non-infringement. For buprenorphine transdermal systems, the principal litigation issues are likely to involve:

• Whether the proposed adhesive composition falls within the asserted claims.
• Whether enhancer concentrations are materially different.
• Whether the generic patch has the same delivery profile.
• Whether method-of-use claims are infringed.
• Whether the patent claims are obvious over earlier transdermal opioid systems.
• Whether manufacturing claims cover the generic's coating process.

A generic company can pursue several routes:

1. Paragraph IV certification with litigation risk.
2. Section viii labeling carve-outs for unpatented uses.
3. Formulation design-around.
4. Post-expiration entry.
5. Licensing or settlement with the patent holder.

Settlement agreements can restrict launch timing, authorized-generic arrangements, or permitted formulations. They should be reviewed with the FTC's pharmaceutical patent settlement disclosures and court filings where available.[4]

What FDA regulatory requirements apply to generic buprenorphine patches?

A generic buprenorphine transdermal system is generally pursued through the ANDA pathway. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug under FDA requirements.[5]

For a transdermal system, regulatory risk extends beyond conventional plasma pharmacokinetics. Development normally requires control of:

• Adhesion performance during wear.
• Drug release from the matrix.
• In vitro permeation through human or validated animal skin models.
• Residual drug content.
• Dose uniformity.
• Patch size and drug loading.
• Peel strength and shear adhesion.
• Skin irritation and sensitization.
• Stability under heat and humidity.
• Extractables and leachables from backing and liner materials.

The label also contains important opioid safety information, including respiratory depression, misuse, abuse, addiction, neonatal opioid withdrawal, and risks associated with heat exposure.[1] Heat can increase buprenorphine absorption and create a safety risk. The backing and matrix therefore have clinical relevance, not merely packaging significance.

What commercial opportunities exist for buprenorphine transdermal excipients?

Generic substitution

The largest opportunity is conventional generic entry. A manufacturer with established transdermal coating and converting capacity can use a reference-matched matrix to target all five strengths. Manufacturing scale, not active pharmaceutical ingredient cost, is likely to be the more important differentiator.

Adhesive-performance products

A differentiated patch could target:

• Better adhesion during sweating and bathing.
• Lower visible residue.
• Easier removal.
• Lower skin irritation.
• Improved adhesion for elderly patients with fragile skin.
• More consistent performance across climates.

These claims may support commercial differentiation, but they can also trigger regulatory and clinical substantiation requirements.

Excipient supply

Specialty excipient suppliers can target pharmaceutical-grade polyisobutylene, polybutene, permeation enhancers, and controlled-grade povidone. Value is highest where suppliers can provide:

• Tight viscosity specifications.
• Low peroxide and impurity levels.
• Consistent enhancer purity.
• Regulatory documentation.
• Low extractables profiles.
• Support for solvent and solvent-free coating processes.

Contract development and manufacturing

CDMOs with hot-melt coating, solvent coating, laminating, slitting, and die-cutting capabilities can offer end-to-end development. Buprenorphine's potency and controlled-substance status raise the value of facilities with validated containment, reconciliation, security, and waste controls.

Line extensions

Potential lifecycle products include:

• Alternative patch sizes.
• Improved skin-adhesion designs.
• Lower-irritation matrices.
• Packaging optimized for humidity protection.
• Regional products using different backing or liner systems.
• Combination treatment strategies, although combination patches face significant regulatory and clinical hurdles.

How strong is the patent estate for buprenorphine transdermal products?

Patent strength is usually highest where claims cover a narrow but commercially essential formulation feature, such as a defined adhesive-plus-enhancer system or a specific delivery rate. Strength is weaker where claims broadly recite known transdermal components without a demonstrated unexpected result.

A practical scoring framework is:

Patent characteristic	Commercial impact
Claims cover the drug-in-adhesive matrix	High
Claims cover only a manufacturing step	Medium, depending on detectability
Claims cover a narrow dosage strength	Medium
Claims cover a labeled indication subject to carve-out	Low to medium
Claims have substantial remaining term	High
Claims have survived validity challenges	High
Claims depend on difficult-to-detect process conditions	Variable

The best design-around strategy is to alter the adhesive platform, enhancer system, or process while preserving equivalent clinical delivery. That approach requires early patent claim charting alongside formulation development.

How does Butrans compare with buprenorphine sublingual products?

Butrans and sublingual buprenorphine products have different commercial and regulatory profiles.

Attribute	Buprenorphine transdermal system	Sublingual buprenorphine
Primary use	Chronic pain	Opioid use disorder and, for some products, pain
Administration	Weekly patch	Daily or repeated oral dosing
Key excipient issue	Adhesion and skin permeation	Taste, dissolution, mucosal absorption
Main manufacturing barrier	Coating, laminating, controlled-substance handling	Tablet or film manufacturing
Main patent focus	Matrix, enhancer, patch construction	Film, tablet, combination, dosing regimen
Generic differentiation	Wear time, irritation, residue	Dissolution, taste, film handling

The transdermal segment has fewer direct dosage-form competitors than oral buprenorphine, but it has higher technical barriers to formulation replication.

What generic entry risks exist for buprenorphine transdermal systems?

Generic entry risk is meaningful when:

• Orange Book patents have expired or are vulnerable.
• Several applicants have filed ANDAs.
• The formulation can be reproduced with common transdermal polymers.
• No clinical advantage differentiates the branded patch.
• Manufacturing capacity is available from multiple CDMOs.
• Payers favor substitution.

Entry risk is lower when:

• Adhesive or enhancer claims remain enforceable.
• The reference product has difficult-to-match in vivo performance.
• The applicant must conduct extensive comparative adhesion work.
• Controlled-substance manufacturing capacity is limited.
• Patent settlements delay launch.
• The branded manufacturer has an authorized-generic strategy.

Revenue exposure is concentrated in the chronic-pain market and depends on payer substitution, opioid prescribing restrictions, generic discounting, and the branded product's ability to retain patients through adhesive or supply advantages.

Key Takeaways

• Butrans uses a polyisobutylene-polybutene drug-in-adhesive matrix with povidone, oleic acid, and levulinic acid.
• Excipient selection controls adhesion, skin permeation, crystallization, residual drug, and seven-day performance.
• The lowest-risk generic strategy is a closely matched matrix rather than a new adhesive platform.
• The strongest commercial opportunities are generic substitution, specialty excipient supply, transdermal CDMO services, and lower-irritation adhesive systems.
• Patent diligence must cover formulation, device, process, method-of-use, Orange Book, Paragraph IV, and settlement records.
• Transdermal buprenorphine has higher development complexity than sublingual products but fewer direct dosage-form competitors.
• Manufacturing controls for controlled substances, coating uniformity, and adhesion testing are material barriers to entry.

FAQs

What is the main excipient in a buprenorphine transdermal patch?

Polyisobutylene is a principal adhesive and matrix-forming excipient. Polybutene modifies tack and rheology, while oleic acid and levulinic acid support skin permeation.

Can an acrylic adhesive be used in a generic buprenorphine patch?

Yes, an acrylic adhesive can be technically feasible, but it may create greater bioequivalence, adhesion, irritation, and patent-design-around risk than a reference-matched polyisobutylene system.

Why is oleic acid used in transdermal buprenorphine?

Oleic acid can increase skin permeation by modifying the lipid structure of the stratum corneum. Its concentration must be controlled because excessive use can increase irritation and delivery variability.

What makes buprenorphine patch manufacturing difficult?

The process must control drug dispersion, coating weight, matrix thickness, enhancer distribution, residual solvent, patch cutting, dose uniformity, adhesion, and controlled-substance reconciliation.

Is a seven-day buprenorphine patch commercially differentiated from daily oral products?

Yes. The patch provides continuous delivery without daily dosing, but it competes against oral products with lower manufacturing complexity and often lower acquisition cost.

References

1. U.S. Food and Drug Administration. (2023). Butrans (buprenorphine) transdermal system prescribing information. Purdue Pharma L.P.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. United States Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov/

4. Federal Trade Commission. (2024). Agreements filed pursuant to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. https://www.ftc.gov/

5. U.S. Food and Drug Administration. (2023). ANDA submissions: Product-specific guidances for industry. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-submissions-product-specific-guidances-industry